166 related articles for article (PubMed ID: 34823323)
41. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
[TBL] [Abstract][Full Text] [Related]
42. [Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary].
Kosztolányi S; Horváth B; Hosnyánszki D; Kereskai L; Sziládi E; Jáksó P; Alizadeh H; Szuhai K; Alpár D; Kajtár B
Orv Hetil; 2019 Jun; 160(24):944-951. PubMed ID: 31433233
[TBL] [Abstract][Full Text] [Related]
43. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
44. The significance of light chain-restricted bone marrow plasma cells after peripheral blood stem cell transplantation for multiple myeloma.
Maia DM; Kell DL; Goates JJ; Warnke RA
Am J Clin Pathol; 1997 Jun; 107(6):643-52. PubMed ID: 9169660
[TBL] [Abstract][Full Text] [Related]
45. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
[TBL] [Abstract][Full Text] [Related]
46. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
[TBL] [Abstract][Full Text] [Related]
47. Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma.
Rabani H; Ziv M; Lavi N; Aviv A; Suriu C; Shalata A; Haddid Y; Tadmor T
Leuk Res; 2020 Dec; 99():106476. PubMed ID: 33171301
[TBL] [Abstract][Full Text] [Related]
48. Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Bacher U; Haferlach T; Kern W; Alpermann T; Schnittger S; Haferlach C
Cancer Genet Cytogenet; 2010 Dec; 203(2):169-75. PubMed ID: 21156229
[TBL] [Abstract][Full Text] [Related]
49. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.
Corradini P; Voena C; Astolfi M; Ladetto M; Tarella C; Boccadoro M; Pileri A
Blood; 1995 Mar; 85(6):1596-602. PubMed ID: 7888677
[TBL] [Abstract][Full Text] [Related]
50. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
[TBL] [Abstract][Full Text] [Related]
51. Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence.
Abaza HM; Youssef SR; Saad AA; Kamal GM; Hegazy MG; Ibrahim RI; Annaka LM
Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):56-63. PubMed ID: 25929730
[TBL] [Abstract][Full Text] [Related]
52. [Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].
Deng SH; Xu Y; Wang YF; Mai YJ; Liu XP; Zhao YZ; Zou DH; Wang Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1685-8. PubMed ID: 17825148
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ; Green DJ; Kwok M; Lee S; Coffey DG; Holmberg LA; Tuazon S; Gopal AK; Libby EN
JAMA; 2022 Feb; 327(5):464-477. PubMed ID: 35103762
[TBL] [Abstract][Full Text] [Related]
54. Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Takamatsu H; Yamashita T; Kurahashi S; Saitoh T; Kondo T; Maeda T; Nakazawa H; Murata M; Narita T; Kuroda J; Hashimoto H; Kawamura K; Miyamoto T; Honda S; Ichinohe T; Atsuta Y; Sunami K
Biol Blood Marrow Transplant; 2019 Mar; 25(3):474-479. PubMed ID: 30423479
[TBL] [Abstract][Full Text] [Related]
55. [Role of cytogenetics in the prognosis of patients with multiple myeloma].
Paluszewska M; Dwilewicz-Trojaczek J; Stańczak H; Brycz-Witkowska J; Chmarzyńska-Mróz E; Rokicka M; Torosian T; Wasiutyński A; Jedrzejczak WW
Pol Arch Med Wewn; 2003 Sep; 110(3):973-9. PubMed ID: 14699690
[TBL] [Abstract][Full Text] [Related]
56. Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods.
Testoni N; Lemoli RM; Martinelli G; Carboni C; Pelliconi S; Ottaviani E; Ruggeri D; Rizzi S; Motta MR; Visani G; Tura S
Bone Marrow Transplant; 1998 Dec; 22(11):1065-70. PubMed ID: 9877268
[TBL] [Abstract][Full Text] [Related]
57. Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease.
Koshiishi M; Kawashima I; Hyuga H; Nakadate A; Matsuura M; Hosokawa E; Sakamoto Y; Suzuki J; Suzuki M; Kumagai T; Yamamoto T; Nakajima K; Tanaka M; Kirito K
Int J Hematol; 2022 Oct; 116(4):544-552. PubMed ID: 35538304
[TBL] [Abstract][Full Text] [Related]
58. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
Vescio RA; Han EJ; Schiller GJ; Lee JC; Wu CH; Cao J; Shin J; Kim A; Lichtenstein AK; Berenson JR
Bone Marrow Transplant; 1996 Jul; 18(1):103-10. PubMed ID: 8832002
[TBL] [Abstract][Full Text] [Related]
59. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
Laï JL; Zandecki M; Mary JY; Bernardi F; Izydorczyk V; Flactif M; Morel P; Jouet JP; Bauters F; Facon T
Blood; 1995 May; 85(9):2490-7. PubMed ID: 7537117
[TBL] [Abstract][Full Text] [Related]
60. [Fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of cytogenetic aberrations of multiple myeloma].
Wang XW; Li JY; Chen LJ; Qian SX; Hong M; Qiao C; Zhang JF; Xu W; Lu H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1316-9. PubMed ID: 19099635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]